[{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Immedica Pharma","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Immedica Pharma"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ Inapplicable"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"CDTI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2025","type":"Financing","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ CDTI","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ CDTI"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PM534","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"VCN Biosciences \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Grifols International"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Abraxane","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will be used to fund Phase Ib-II clinical trials of OMTX705, a first-in-class, novel ADC targeting fibroblast activation protein (FAP), to treat metastatic solid tumors.

                          Product Name : OMTX705

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          January 27, 2025

                          Lead Product(s) : OMTX705,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : CDTI

                          Deal Size : $25.6 million

                          Deal Type : Financing

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with myelodysplastic syndrome.

                          Product Name : ORY-1001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 23, 2025

                          Lead Product(s) : Iadademstat,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with venetoclax & azacitidine in patients with acute myeloid leukemia.

                          Product Name : ORY-1001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Iadademstat,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with venetoclax & azacitidine in patients with acute myeloid leukemia.

                          Product Name : ORY-1001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 09, 2024

                          Lead Product(s) : Iadademstat,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinas...

                          Product Name : ORY-1001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 15, 2023

                          Lead Product(s) : Iadademstat,Gilteritinib Fumarate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PM534, a novel marine-derived anti-tumor compound, has been tested in the laboratory, both in cell cultures and in animals. In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other...

                          Product Name : PM534

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 30, 2022

                          Lead Product(s) : PM534

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with ...

                          Product Name : VCN-01

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          November 03, 2022

                          Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Theriva Biologics

                          Deal Size : $4.7 million

                          Deal Type : Acquisition

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.

                          Product Name : VCN-01

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          August 02, 2022

                          Lead Product(s) : VCN-01,Paclitaxel,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Theriva Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional pat...

                          Product Name : VCN-01

                          Product Type : Microorganism

                          Upfront Cash : $4.7 million

                          December 14, 2021

                          Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Grifols International

                          Deal Size : $77.4 million

                          Deal Type : Acquisition

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.

                          Product Name : Zepzelca

                          Product Type : Cytotoxic Drug

                          Upfront Cash : $2.1 million

                          April 29, 2020

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Immedica Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank